Ref: NEPHROPLUS/SE/56

July 06, 2026

To
BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001
Scrip Code: 544647
Through: BSE Listing Centre

To
National Stock Exchange of India Limited
5th Floor, Exchange Plaza, Bandra (E),
Mumbai – 400 051
Scrip Symbol: NEPHROPLUS
Through: NEAPS

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**"), we hereby inform you that this has reference to our letter bearing reference no. NEPHROPLUS/SE/34 dated May 19, 2026, whereby the Company had informed the Stock Exchanges regarding the approval granted by the Board of Directors for providing collateral/security support in favour of Citibank N.A. ("**Citibank**") and/or its affiliates, branches or designated lending offices, for the benefit of Nephrocare Health Services International Pte. Ltd. ("**NHSI**"), Singapore, an overseas wholly-owned subsidiary of the Company.

In this regard, we hereby inform you that the Company has provided the aforesaid collateral/security support in favour of Citibank for the benefit of NHSI on July 06, 2026, which became effective from the same date, to enable NHSI to avail fund-based and/or non-fund-based credit facilities. The aggregate financial commitment undertaken by the Company pursuant to the aforesaid transaction amounts to USD 3,300,000 (equivalent to INR 31.22 Crore).

The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as **Annexure I**.

The aforesaid information is also being made available on the Company's website at www.nephroplus.com

For Nephrocare Health Services Limited
(Formerly Nephrocare Health Services Private Limited)

Kathri Kishore

Digitally signed by Kathri Kishore
Date: 2026.07.06 17:27:25 +05'30'

Kishore Kathri
Company Secretary & Compliance Officer
ICSI M.No. F9895

Encl: a/a

ANNEXURE I

Sr. No.	Particulars	Description
1.	Name of party for which such guarantees or indemnity or surety was given	Nephrocare Health Services International Pte. Ltd. (**NHSI**), Singapore, an overseas wholly-owned subsidiary of the Company.
2.	Whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The transaction has been undertaken for the benefit of the said overseas WOS entity. The promoter(s), promoter group and group companies do not have any direct or indirect interest in the transaction, other than to the extent of their shareholding interest in the Company. The transaction has been undertaken in the ordinary course of business and on an arm's length basis.
3.	Brief details of such guarantee or indemnity or becoming a surety viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee;	The Company has provided collateral/security support on July 06, 2026, in favour of **Citibank N.A.** ("**Citibank**") and/or its affiliates, branches or designated lending offices, for the benefit of Nephrocare Health Services International Pte. Ltd. (**NHSI**), Singapore, an overseas wholly-owned subsidiary of the Company. The aggregate financial commitment undertaken by the Company is USD 3,300,000 (equivalent to INR 31.22 Crore).
4.	Impact of such guarantees or indemnity or surety on listed entity	The transaction results in a financial commitment by the Company of USD 3,300,000 (equivalent to INR 31.22 Crore) by way of providing collateral/security support in favour of Citibank for the benefit of Nephrocare Health Services International Pte. Ltd., Singapore, an overseas wholly-owned subsidiary of the Company. The transaction creates a contingent financial exposure on the Company to the extent of the aforesaid amount. Other than the aforesaid contingent financial exposure, no immediate impact on the operations, liquidity or cash flows of the Company is envisaged.